… Program for FY 2018 a. Adoption of Modified PSI 90: Patient Safety and Adverse Events Composite (NQF #0531) (1) Background (2) Overview of the Measure Changes (3) Risk Adjustment (4) Adoption of the NQF-Endorsed Version of the Modified PSI 90 b. Applicable Time Periods for the F…
…cryl 3,5 dinitrotriazole); j. TACOT (tetranitrobenzotriazolobenzotriazole) (CAS 25243 36 1); 33. “Explosives” not listed elsewhere in this list having a detonation velocity exceeding 8,700 m/s, at maximum density, or a detonation pressure exceeding 34 GPa (340 kbar); 34. [Reserve…
…3,5-dinitrotriazole); or (ix) TACOT (tetranitrobenzotriazolobenzotriazole) (CAS 25243-36-1); (37) Energetic ionic materials melting between 343 K (70 °C) and 373 K (100 °C) and with detonation velocity exceeding 6800 m/s or detonation pressure exceeding 18 GPa (180 kbar); or (38)…
…3,5-dinitrotriazole); or (ix) TACOT (tetranitrobenzotriazolobenzotriazole) (CAS 25243-36-1); (37) Energetic ionic materials melting between 343 K (70 °C) and 373 K (100 °C) and with detonation velocity exceeding 6800 m/s or detonation pressure exceeding 18 GPa (180 kbar); or (38)…
…3,5-dinitrotriazole); or (ix) TACOT (tetranitrobenzotriazolobenzotriazole) (CAS 25243-36-1); (37) Energetic ionic materials melting between 343 K (70 °C) and 373 K (100 °C) and with detonation velocity exceeding 6800 m/s or detonation pressure exceeding 18 GPa (180 kbar); or (38)…